Delving into the Latest Updates on Pretomanid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Pretomanid (USAN/INN), 普瑞玛尼, PA 824

+ [5]

Target

CYP2C19 x CYP2C8

Mechanism

CYP2C19 inhibitors(cytochrome P450 family 2 subfamily C member 19 inhibitors), CYP2C8 inhibitors(cytochrome P450 family 2 subfamily C member 8 inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Drug-Resistant TuberculosisMultidrug resistant pulmonary tuberculosisTuberculosis, Multidrug-Resistant+ [3]

Inactive Indication

Infectious Lung Disorder

Originator Organization

Novartis Pharma AG

Active Organization

Viatris, Inc.

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.Mylan IRE Healthcare Ltd.

+ [5]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (14 Aug 2019),

Extensively Drug-Resistant TuberculosisTuberculosis

RegulationFast Track (US), Orphan Drug (KR), Orphan Drug (AU)

Login to view timeline

Structure/Sequence

Molecular FormulaC14H12F3N3O5

InChIKeyZLHZLMOSPGACSZ-NSHDSACASA-N

CAS Registry187235-37-6

A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB).
A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) measurements over the first 6 weeks of treatment, and will have acceptable safety and tolerability over 8 weeks of treatment relative to standard of care [(SOC) isoniazid/rifampicin/pyrazinamide/ethambutol (HRZE)].
The study will run for 52 weeks, inclusive of 26 weeks of TB treatment comprised of 8 weeks of experimental or SOC treatment (based on treatment arm assignment) followed by 18 weeks of SOC treatment with 45 participants in each experimental treatment arm and at least 90 participants in the SOC arm.

Start Date01 Mar 2025

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+1]

NCT06441006

/ Not yet recruitingPhase 3IIT

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

PRISM-TB is an international, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, noninferiority Phase 3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB).
The trial objective is to evaluate whether stratified medicine treatment strategies for FQ-S MDR/RR-TB, defined by a pre-specified risk stratification algorithm, have noninferior efficacy to a one-size-fits-all control regimen (the local standard-of-care [SOC] regimen consistent with preferred regimen(s) in international guidelines), as measured by TB-related unfavorable outcomes at Week 73.

Start Date15 Jan 2025

Sponsor / Collaborator

The University of California, San Francisco

[+1]

NCT03896750

/ RecruitingPhase 1IIT

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

This is a Phase 1, open-label, single-dose, sequential group study to compare the safety and pharmacokinetics (PK) of pretomanid in the following groups of participants: 1) participants with severe renal impairment including those with end stage renal disease (ESRD) not on dialysis, and participants with mild or moderate renal impairment, designated as Groups 2, 3, and 4, respectively; and 2) participants with normal renal function matched to the above renal impairment groups, designated as Groups 1A, 1B, and 1C, respectively.
The study will be conducted following a reduced PK study design in Part A. Part A will enroll participants from Group 1A (i.e., 6 healthy matched controls) and Group 2 (i.e., 6 participants with severe renal impairment and ESRD, not on dialysis). A decision to proceed to Part B will be made after the PK of pretomanid, and safety in participants enrolled in Part A have been reviewed. If Part A demonstrates at least a 50% increase in pretomanid area under the plasma concentration-time curve (AUC) in Group 2 (severe renal impairments and ESRD, not on dialysis) relative to the exposures in Group 1A (matched participants with normal renal function), then the reduced PK study will extend to the full PK study to enroll participants into Part B (i.e., to investigate mild and moderate renal impairment). All Part B groups (1B, 1C, 3, and 4) will be enrolled concurrently.
If the reduced PK study shows at least a 50% increase in AUC in patients with severe renal impairment and patients with ESRD not yet on dialysis relative to the matched healthy controls, a "full PK" renal impairment study in patients with all intermediate levels of renal function impairment should be conducted. Otherwise, no further study is recommended.
The approximate patient involvement will be 3 months. The primary objective is to evaluate the PK profiles of pretomanid in plasma and urine after a single oral dose of 200 mg in participants with renal impairment compared to matched healthy controls.

Start Date27 Mar 2024

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Pretomanid

Login to view more data

100 Translational Medicine associated with Pretomanid

Login to view more data

100 Patents (Medical) associated with Pretomanid

Login to view more data

664

Literatures (Medical) associated with Pretomanid

01 Feb 2025·BIOORGANIC & MEDICINAL CHEMISTRY

Structural toxicity relationship (STR) of linezolid to mitigate myelosuppression and serotonergic toxicity

Review

Author: Patel, Harun ; Shaikh, Matin

Tuberculosis (TB) remains a significant global health challenge, with multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains posing severe threats to treatment efficacy. Linezolid, a key component of the BPaL (Bedaquiline, Pretomanid and Linezolid) regimen, has demonstrated substantial efficacy against MDR-TB and XDR-TB. However, its clinical utility is often limited by side effects such as myelosuppression and monoamine oxidase (MAO) inhibition, linked to its mechanism of action. This perspective centres on the structural toxicity relationship (STR) of Linezolid and its analogues, exploring modifications to the C-ring and C-5 position that aim to reduce these toxicities while maintaining or enhancing antibacterial activity. Several promising analogues have been identified that exhibit reduced myelosuppression and MAO inhibition, highlighting the potential for developing safer Linezolid derivatives. The findings underscore the importance of continued research into the structure toxicity relationships of oxazolidinones to improve the therapeutic profiles of these essential drugs in combating drug-resistant TB.

01 Feb 2025·Lancet Global Health

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Article

Author: Tigay, Zinaida ; Fielding, Katherine ; Liverko, Irina ; Rassool, Mohammed ; Usmanova, Ruzilya ; Kazounis, Emil ; Butabekov, Ilhomjon ; Moodliar, Ronelle ; Nyangweso, George Mokua ; Nyang'wa, Bern-Thomas ; Singh, Maninder Pal ; Jolivet, Pascal ; Abdrasuliev, Tleubergen ; Sweeney, Sedona ; Laurence, Yoko V ; Dodd, Matthew ; Motta, Ilaria ; Aw, Pei Sun ; Berry, Catherine ; Moe, Soe ; Solodovnikova, Varvara ; Parpieva, Nargiza ; Samieva, Nazgul

BACKGROUND:

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. Following a change to WHO rifampicin-resistant tuberculosis treatment guidelines, countries are facing difficult decisions about when and how to incorporate new drug regimens into national guidelines. We aimed to assess the probability of BPaL-based regimens being cost-saving using data collected in the TB-PRACTECAL trial.

METHODS:

This economic evaluation using a cost-utility analysis was embedded in five TB-PRACTECAL trial sites in Belarus, Uzbekistan, and South Africa. Between Nov 19, 2020, and Sept 27, 2022, we collected detailed primary unit cost data in six hospitals and four ambulatory health facilities and collected data on patient-incurred costs from 73 trial participants. The primary efficacy endpoint of the main trial, a composite of unfavourable outcomes (death, disease recurrence, treatment failure, early discontinuation of therapy, withdrawal, or loss to follow-up) and clinically important safety outcomes by 72 weeks of follow-up were incorporated into the analysis. Societal perspective cost data and effect outcome data were input into a Markov model to estimate the cost per disability-adjusted life-year (DALY) averted by BPaL-based regimens compared with the standard of care over a 20-year time horizon. We conducted a range of univariate and probabilistic sensitivity analyses to test our findings.

FINDINGS:

BPaL-based regimens averted a mean of 1·28 DALYs and saved a mean of US$14 868 (SD 291) per person from the provider perspective compared with standard-of-care regimens over 20 years. Patient-incurred costs were reduced by a mean of $172 (SD 0·84) in BPaL-based regimen groups compared with standard of care. The main cost drivers for both providers and patients were inpatient bed-days; the duration of the inpatient period varied across countries. Varying a range of model parameters affected the degree of cost savings but did not change the finding that BPaL-based regimens are cost-saving compared with standard of care.

INTERPRETATION:

This trial-based evidence adds to consistent indications from modelling studies that BPaL-based regimens are cost-saving for both the patient and health system. Urgent implementation of BPaL-based regimens in countries with a high burden of tuberculosis could improve treatment of rifampicin-resistant tuberculosis, reduce pill burden, and free up desperately needed resources within the health system.

FUNDING:

Médecins Sans Frontières.

01 Feb 2025·BIOORGANIC CHEMISTRY

Recent advancements in the quest of benzazoles as anti-Mycobacterium tuberculosis agents

Review

Author: Chakraborti, Asit K ; Saha, Nirjhar ; Dhameliya, Tejas M ; Patel, Kshitij I

Tuberculosis (TB) remains a global health challenge, claiming numerous lives each year, despite recent advancements in drug discovery and treatment strategies. Current TB treatment typically involves long-duration chemotherapy regimens that are often accompanied by adverse effects. The introduction of new anti-TB drugs, such as Bedaquiline, Delamanid, and Pretomanid, offers hope for more effective treatment, although challenges persist keeping the quest to find new anti-TB chemotypes an incessant exercise of medicinal chemists. Towards this initiative, the benzazoles continue to draw attention and have been recognised as new anti-TB scaffolds. Benzazole-containing compounds emerged as new chemotypes with potential to offer a versatile platform for new anti-TB drug design to generate new leads for further optimization. The elucidation of their chemical properties, biological effects, and potential mechanisms of action, would lead to identify innovative candidates for TB therapy. As medicinal chemists delve deeper into the SARs and mechanisms of action of benzazole derivatives, new opportunities for creating effective and safe anti-TB medications arise. This review highlights the potential impact of benzazole-based compounds on the search for new therapeutic agents against tuberculosis, emphasizing the importance of continued research and innovation in the field.

19

News (Medical) associated with Pretomanid

15 Jan 2025

·www.tballiance.org

Historically Successful Global Access Campaign for Pretomanid and BPaL-based Regimens Continues with Major Milestones in BRICS Countries

January 15, 2025 Throughout 2024, one of TB Alliance’s foremost priorities has been ensuring that pretomanid and BPaL-based regimens reach all people with drug-resistant TB (DR-TB) around the world. To meet this challenge, TB Alliance has been working with and empowering a diverse set of stakeholders to help scale access to this treatment more quickly and widely than had been achieved for a TB therapy in the modern era. We are heartened to share an update on approval and programmatic implementation milestones in the five BRICS countries, four of which are among the world’s ten highest DR-TB burden countries. South Africa continues to make dramatic progress against DR-TB South Africa is a prime example of what a country can achieve when they truly commit to tackling DR-TB. Between 2015 and 2022, South Africa reduced its DR-TB burden by nearly 80%. Following first approval of pretomanid, South Africa rapidly implemented the BPaL Clinical Access Programme (BCAP), which helped inform local implementation. Working with the National TB Programme and a local partner, TB Alliance helped develop a national implementation plan. South Africa is firmly on the path toward full national implementation of BPaL-based regimens launched on September 1, 2023. By November 2024, more than 5,000 individuals had been enrolled on the treatments. At least 90% of all individuals who are eligible for these regimens are now receiving them. Brazil rolls out BPaL/M following visit to PeerLINC Knowledge Hub Brazil, a leader in implementing health innovations and making them rapidly available to all who need them in the country, began rolling out BPaL/M in December 2024. This follows a training and capacity building visit by a delegation of TB experts and policymakers from the Brazilian National TB Program to the PeerLINC Knowledge Hub in Manila. PeerLINC is a collaboration between TB Alliance and the Tropical Disease Foundation, Inc. (TDF) and works closely with the Department of Health, Philippines and provides practical training, technical support and peer-to-peer thought partnership to NTPs to develop implementation plans and help speed programmatic implementation of new TB technologies. India issues national guidelines; initiates BPaL rollout With the largest DR-TB burden of any country in the world, India was one of the first countries in the world to approve pretomanid and the BPaL regimen. However, the path from approval to national implementation requires many steps. Upon approval, a study on BPaL was conducted by Indian researchers under India’s National TB Elimination Programme to generate local evidence and confirm the global clinical trial results of the regimen. Having completed this study, India updated its national treatment guidelines in December 2024 to include BPaL/M. National and regional trainings have been rolled out rapidly by the Central TB Division which will enable roll-out of BPaL/M under programmatic settings. Russia approves pretomanid/BPaL One of only three countries in the world that reports 30,000 or more cases of DR-TB annually, Russia is a key high DR-TB burden country with a complex and independent approval process for new medicines. Regulatory approval for pretomanid and BPaL was granted in December 2024. Plans to make pretomanid available in the country have commenced. China approves pretomanid/BPaL With the world’s fourth-highest DR-TB burden, pretomanid and BPaL could prove to be a crucial tool to speed up China’s intention to eliminate DR-TB and build on the country’s efforts that have already led to a reduction in overall DR-TB burden by approximately 50% over the previous decade. In December 2024, pretomanid and BPaL received regulatory approval in China and TB Alliance is working closely with national stakeholders including the China Anti-Tuberculosis Association and the manufacturer in the country to ensure rapid roll-out of the regimen. PeerLINC Knowledge Hub Mylan Secures DCGI Approval in India for Pretomanid, a Treatment for Highly Drug-Resistant Forms of Tuberculosis

Drug ApprovalClinical Study

13 Jan 2025

·www.drugs.com

Shorter Treatment Regimens Recommended for Tuberculosis

MONDAY, Jan. 13, 2025 -- In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine , updated recommendations are presented for the treatment of tuberculosis (TB) in children and adults. Jussi J. Saukkonen, M.D., from the Boston Veterans Administration Health Care System, and colleagues updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies are available on a regular basis. The evidence was reviewed and recommendations made. The authors note that new recommendations for drug-susceptible TB include use of a novel four-month regimen for individuals with pulmonary TB and a shortened four-month regimen, instead of the six-month regimen, for nonsevere TB in children. Use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin are included as recommendations for drug-resistant TB. For adolescents aged 14 years and older and adults with rifampin-resistant pulmonary TB, a six-month bedaquiline, pretomanid, and linezolid regimen is as efficacious and safe as the current 15-month or longer regimen. "There has been a quest and concerted effort to develop shorter treatments for TB, after decades of little drug development," Saukkonen said in a statement. "With recent studies we have been able to shorten the regimen durations for both drug-susceptible and drug-resistant TB for most patients, down to four and six months, respectively." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 3

06 Nov 2024

·www.tballiance.org

TB Alliance Applauds WHO Prequalification of Macleods Pretomanid Product

NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received prequalification from the World Health Organization (WHO) for its 200mg tablet of pretomanid, which provides an assurance of safety, quality and efficacy for drug-resistant tuberculosis (DR-TB) patients and their healthcare providers. Pretomanid was developed by the nonprofit TB Alliance and is a key component of the BPaL/M regimens, which have shortened the time needed to treat DR-TB to six months. Previously, most DR-TB treatment regimens lasted 9-18 months or sometimes longer. By partnering with Macleods and other predominantly generic manufacturers, TB Alliance aims to expand access to this life-saving treatment through a strategic commercialization approach – helping to deliver on our commitment to ensure an affordable, sustainable and competitive market for all our new TB products. Macleods has agreed to commercialize pretomanid in approximately 140 countries and territories. According to new data from the WHO, an estimated 400,000 people developed DR-TB infections in 2023, with only 176,000 people starting treatment. TB is the world’s deadliest infectious disease. Macleods' new product will accelerate our continued efforts to reliably provide more patients with access to this life-saving regimen. WHO prequalification is a standard for medical products required for procurement by many UN agencies, multilateral organizations like the Global Fund and Stop TB’s Global Drug Facility for supplying low- and middle-income countries. By obtaining WHO pre-qualification for pretomanid, Macleods will be able to service demand for this life saving medicine from these agencies. WHO Global TB Report 2023 TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB

Clinical Study

100 Deals associated with Pretomanid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10722	Pretomanid	J04	DB05154

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Drug-Resistant Tuberculosis	HK	Shanghai Fosun High Technology (Group) Co., Ltd.	15 Dec 2022
Multidrug resistant pulmonary tuberculosis	KR	Viatris, Inc.	15 Oct 2021
Tuberculosis, Multidrug-Resistant	EU	Mylan IRE Healthcare Ltd.	31 Jul 2020
Tuberculosis, Multidrug-Resistant	IS	Mylan IRE Healthcare Ltd.	31 Jul 2020
Tuberculosis, Multidrug-Resistant	LI	Mylan IRE Healthcare Ltd.	31 Jul 2020
Tuberculosis, Multidrug-Resistant	NO	Mylan IRE Healthcare Ltd.	31 Jul 2020
Extensively Drug-Resistant Tuberculosis	US	Mylan Ireland Ltd.	14 Aug 2019
Tuberculosis	US	Mylan Ireland Ltd.	14 Aug 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Tuberculosis	Phase 3	GE	Global Alliance for TB Drug Development	21 Nov 2017
Pulmonary Tuberculosis	Phase 3	MD	Global Alliance for TB Drug Development	21 Nov 2017
Pulmonary Tuberculosis	Phase 3	RU	Global Alliance for TB Drug Development	21 Nov 2017
Pulmonary Tuberculosis	Phase 3	ZA	Global Alliance for TB Drug Development	21 Nov 2017
Infectious Lung Disorder	Phase 3	ZA	Global Alliance for TB Drug Development	01 Mar 2015
Rifampicin resistant tuberculosis	Phase 1	BR	Global Alliance for TB Drug Development	03 Oct 2023
Rifampicin resistant tuberculosis	Phase 1	IN	Global Alliance for TB Drug Development	03 Oct 2023
Rifampicin resistant tuberculosis	Phase 1	ZA	Global Alliance for TB Drug Development	03 Oct 2023
Rifampicin resistant tuberculosis	Phase 1	TZ	Global Alliance for TB Drug Development	03 Oct 2023
Rifampicin resistant tuberculosis	Phase 1	TH	Global Alliance for TB Drug Development	03 Oct 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04179500 (PaSEM, CTgov)	Phase 2	Multidrug resistant pulmonary tuberculosis \| Tuberculosis, Multidrug-Resistant	26	BPaMZ (BPaMZ)	ygnmubsoft(qyujehbfas) = qijfszldqz ojfrnsmqze (chxzuuxhxf, holajgzeha - jhyxyxoshk) View more	-	19 Sep 2024
				moxifloxacin+bedaquiline+pyrazinamide (BPaMZ Baseline)	upetejuirr(ckolewnptg) = vnpfncztnp snnxulfszo (rvanrdzydz, qkvtaznupa - zunfylnwoo) View more
NCT03338621 (SimpliciTB, Pubmed \| Lancet Infect Dis)	Phase 2	Pulmonary Tuberculosis	455	Bedaquiline-pretomanid-moxifloxacin-pyrazinamide (BPaMZ) 4 months	higefjvaip(fxnxjqzmaj) = three participants [1%] fyaqfhpkan (nrxrxczupt ) View more	Positive	01 Sep 2024
NCT02589782 (TB-PRACTECAL, Pubmed) Manual	Phase 2/3	Extensively Drug-Resistant Tuberculosis	552	rifampicin (Standard care)	ozdwwkuzyo(cryuxyuytw) = vzpnxycpnl clfxwvqrfc (iglenqqibm ) View more	Positive	01 Feb 2024
				rifampbedaquilinepretomanidlinezolidmoxifloxacin (BPaLM)	ozdwwkuzyo(cryuxyuytw) = cmgygdmnft clfxwvqrfc (iglenqqibm ) View more
NCT03338621 (SimpliciTB, CTgov)	Phase 2/3	Multidrug resistant pulmonary tuberculosis \| Tuberculosis, Multidrug-Resistant	455	ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR)	oerslbureg(mihvbbgfve) = fxulpaxaag fylptamflb (rgcvfelthk, mtvjpbmxwd - xugpadrgmw) View more	-	08 Nov 2023
				4BPaMZ (Drug Sensitive-TB 4BPaMZ)	oerslbureg(mihvbbgfve) = jqcyekbvoo fylptamflb (rgcvfelthk, dfniboduct - sdwolgfcms) View more
NCT02256696 (CTgov)	Phase 2	Pulmonary Tuberculosis	157	PA-824+Rifampin+Isoniazid+Pyrazinamide (Arm 1)	hpzixvwmpg(whurrnrivl) = ozrqbxwguz fzpuhzunmx (stjejowmbx, xgpjlaprmh - hjxsipeysv) View more	-	18 Jul 2023
				PA-824+Rifabutin+Isoniazid+Pyrazinamide (Arm 2)	hpzixvwmpg(whurrnrivl) = tkbprplopd fzpuhzunmx (stjejowmbx, eiuphbxlie - jafdttfbeu) View more
NCT03086486 (ZeNix, CTgov)	Phase 3	Extensively Drug-Resistant Tuberculosis \| Pulmonary Tuberculosis \| Infectious Lung Disorder	181	Placebo Linezolid+Pretomanid+Linezolid+Bedaquiline (1200mg L x 26 Weeks + Pa + B)	lhzdtbpyus(eklxavxace) = zlkeptgegm jnrairjidl (vzmyrhazzs, vrwktnwrcd - ucpagyvzxg) View more	-	29 Jun 2023
				Placebo Linezolid+Pretomanid+Linezolid+Bedaquiline (1200 mg L x 9 Weeks + Pa + B)	lhzdtbpyus(eklxavxace) = qoaxiyhpwf jnrairjidl (vzmyrhazzs, kambcxbvne - kbnqiyhneq) View more
NCT03086486 (ZeNix, Pubmed \| N Engl J Med)	Phase 3	Tuberculosis, Multidrug-Resistant	181	Bedaquiline-pretomanid-linezolid with linezolid 1200mg for 26 weeks	avwrwidttk(aetwzsrfkg) = the linezolid dose was modified (i.e., interrupted, reduced, or discontinued) in 51%, 30%, 13%, and 13% of participants who received bedaquiline-pretomanid-linezolid with linezolid at a dose of 1200 mg for 26 weeks or 9 weeks or 600 mg for 26 weeks or 9 weeks, respectively vjdfgmbpjg (xqixvqswfl ) View more	Positive	01 Sep 2022
				Bedaquiline-pretomanid-linezolid with linezolid 1200mg for 9 weeks
NCT02256696 (Pubmed \| Antimicrob Agents Chemother)	Phase 1	Tuberculosis	157	Pretomanid + Rifampin	zbduqvegnx(fsivryngcz) = nhxojbuzta xeleuhmcew (dyjjraeqnx ) View more	-	20 Jan 2021
				Pretomanid + Rifabutin	zbduqvegnx(fsivryngcz) = dxpvhtubre xeleuhmcew (dyjjraeqnx ) View more
NCT03086486 (ZeNix, IAS2021)	Not Applicable	Tuberculosis	181	Bedaquiline (B)	vcyhqkxoxq(pjpbiwemay) = qxndmneozb tqmlcgijzy (pfdpnnvbrh )	-	01 Jan 2021
NCT02333799 (Nix-TB, Pubmed)	Phase 3	Multidrug resistant pulmonary tuberculosis	109	Bedaquiline (B)	rljppeqzkr(fxgyffnyby) = qcsmahkcmc wjmgloeivy (zuuzovnxlh ) View more	-	05 Mar 2020
				Pretomanid (Pa)	gwveanxnkj(qoesjsvpeg) = qmyslpohah odkvpzanoc (djvdkaowsp ) View more